An automated method for the simultaneous measurement of azole antifungal drugs in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry

Analytical and Bioanalytical Chemistry

Volumn 404, Issue 2, 2012, Pages 513-523

  Couchman, L ^a   Buckner, S L ^a   Morgan, P E ^a   Ceesay, M M ^a   Pagliuca, A ^a   Flanagan, R J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Automated sample preparation; Azole antifungals; Itraconazole; Posaconazole; TurboFlow MS MS; Voriconazole

Indexed keywords

ANTIFUNGALS; ITRACONAZOLE; POSACONAZOLE; SAMPLE PREPARATION; TURBOFLOW MS/MS; VORICONAZOLE;

AUTOMATION; CALIBRATION; DRUG INTERACTIONS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING;

DRUG PRODUCTS;

ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

AUTOMATION; BLOOD; CALIBRATION; CONFERENCE PAPER; HUMAN; LIQUID CHROMATOGRAPHY; METHODOLOGY; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANTIFUNGAL AGENTS; AUTOMATION; AZOLES; CALIBRATION; CHROMATOGRAPHY, LIQUID; HUMANS; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

ARIA;

EID: 84865521282     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6176-3     Document Type: Conference Paper

References (36)

1. Bow E, Loewen R, Cheang M, Schacter B (1995) Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukaemia: the pathogenic role of the antileukaemic regimen. Clin Inf Dis 21:361-369
2. Bow E (1998) Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 41:1-5
3. Maertens J (2007) Evaluating prophylaxis if invasive fungal infections in patients with haematological malignancies. Eur J Haematol 78:275-282
4. Cornely O, Bohme A, Buchheidt D et al (2009) Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. Haematologica 94:113-122
5. Groll A, De Lucca A, Walsh T (1998) Emerging targets for the development of novel antifungal therapeutics. Trends Microbiol 6:117-124
6. Heimark L, Shipkova P, Greene J et al (2002) Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J Mass Spectrom 37:265-269
7. Lewis RE (2011) Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy. Curr Opin Infect Dis 24(Suppl 2):S14-S29
8. Hope W, Billaud E, Lestner J, Denning D (2008) Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 21:580-586
9. Goodwin ML, Drew RH (2008) Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61:17-25
10. Andes D, Pascual A, Marchetti O (2009) Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:24-34
11. Lestner J, Roberts S, Moore C, Howard S, Denning D, Hope W (2009) Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 49:928-930
12. Hostetler JS, Heykants J, Clemons K, Woestenborghs R, Hanson LH, Stevens DA (1993) Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 37:2224-2227
13. Purkins L,Wood N,Ghahramani P et al (2002) Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546-2553
14. Brüggemann RJ, Donnelly JP, Aarnoutse RE et al (2008) Therapeutic drug monitoring of voriconazole. Ther Drug Monit 30:403-411
15. Gubbins P, Krishna G, Sansone-Parsons A et al (2006) Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 50:1993-1999
16. Ullmann A, Cornely O, Burchardt A et al (2006) Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50:658-666
17. Krishna G, Martinho M, Chandrasekar P, Ullmann A, Patino H (2007) Pharmacokinetics of oral posaconazole in allogenic haematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636
18. Glasmacher A, Hahn C, Leutner C et al (1999) Breakthrough invasive fungal infections in patients after prophylaxis with itraconazole. Mycoses 42:443-451
19. Smith J, Safdar N, Knasinski Vet al (2006) Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:1570-1572
20. Pascual A, Calandra T, Bolay S et al (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201-211
21. Edge T (2003) Turbulent flow chromatography in bioanalysis. In: Wilson ID (ed) Handbook of analytical separations, vol 4. Elsevier Science B.V, Amsterdam, pp 91-128
22. Morgan PE, Couchman L, Robinson S, McDonnell S, Flanagan RJ (2010) Analysis of clozapine and norclozapine in plasma using online sample preparation and LC-MS/MS. The Column 6:10-16
23. Couchman L, Nooijen P, Birch M, Robinson S, Flanagan RJ (2010) Simultaneous and sensitive analysis of dasatinib, imatinib, norimatinib and nilotinib in human plasma using TurboFlow LCMS/M.S. Toxichem Krimtech 77:218
24. Chahbouni A, Wilhelm AJ, den Burger JC, Sinjewel A, Vos RM (2010) Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum. Ther Drug Monit 32:453-457
25. Alffenaar JWC, Wessels A, van Hateren K, Greijdanus B, Kosterink J, Uges D (2010) Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B 878:39-44
26. Ramos L, Brignol N, Bakhtiar R, Ray T, McMahon LM, Tse FL (2000) High-throughput approaches to the quantitative analysis of ketoconazole, a potent inhibitor of cytochrome P450 3A4, in human plasma. Rapid Commum Mass Spectrom 14:2282-2293
27. FDA/CDER (Food and Drug Administration/Center for Drug Evaluation and Research) (2001) Guidance for industry. Bioanalytical method validation. See http://www.fda.gov/cder/guidance/4252fnl.htm (last checked 5 May 2009)
28. Bonfiglio R, King RC, Olah TV, Merkle K (1999) The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom 13:1175-1185
29. Couchman L, Birch M, Ireland R et al (2012) An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 403:1685-1695
30. Buckner SL, Ceesay MM, Pagliuca A, Morgan PE, Flanagan RJ (2011) Measurement of posaconazole, itraconazole and hydroxyitraconazole in plasma/serum by HPLC with fluorescence detection. Ther Drug Monit 33:735-741
31. Boogaerts M, Verhoef G, Zachee P, Demuuynck H, Verbist L, de Beule K (1989) Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32:103-108
32. Hardin T, Graybill J, Fetchick R, Woestenborghs R, Rinaldi M, Kuhn J (1988) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310-1313
33. FDA/CDER (2009) Posaconazole. FDA briefing document. See http://www.fda.gov/cder/foi/nda/2006/022003s000-NoxafilTOC.htm (last checked 27 July 2009)
34. Thomson G, Rinaldi M, Patterson T, Lewis J (2009) Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 53:2223-2224
35. Lebeaux D, Lanternier F, Elie C et al (2009) Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 53:5224-5229
36. Matsumoto K, Ikawa K, Abematsu K et al (2009) Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 34:91-94